NCT01432574View on ClinicalTrials.gov

Study of Gardasil in Mid-Adult Males (MAM)

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 19, 2013

Primary Completion Date

May 23, 2014

Study Completion Date

November 3, 2020

Conditions
Human Papillomavirus
Interventions
BIOLOGICAL

Gardasil

The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

62209

National Institute of Public Health, Mexico, Cuernavaca

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01432574 - Study of Gardasil in Mid-Adult Males (MAM) | Biotech Hunter | Biotech Hunter